Retrospective analysis of sorafenib in liver transplant recipients of HCC found that adjuvant sorafenib was not associated with overall survival. Recipients were observed to have shorter recurrence free survival https://tinyurl.com/4s797t2w4s797t2w
Comments
Log in with your Bluesky account to leave a comment
Comments